Sheel Biotech Limited reported a 9.3% rise in net profit to ₹117.56 crore for the financial year ended March 31, 2026, compared to ₹107.55 crore in the previous year. Revenue from operations increased 8.1% to ₹1,100.22 crore from ₹1,017.53 crore in FY25. The board of directors approved the audited standalone financial results for the year on May 28, 2026.

The company’s total income for FY26 stood at ₹1,107.35 crore, up from ₹1,022.71 crore in the prior year. Total expenses increased to ₹967.19 crore from ₹894.48 crore. Earnings per share (EPS) for the year stood at ₹6.69, compared to ₹7.28 in the previous year. No dividend was declared or paid during the year by the company.

Financial Performance

The profit before tax for the year increased to ₹140.16 crore from ₹128.23 crore in FY25. The tax expense for the year included a current tax of ₹24.34 crore and a deferred tax of ₹0.37 crore. Finance costs rose to ₹19.15 crore from ₹17.66 crore, while depreciation and amortization expenses increased to ₹10.66 crore from ₹9.00 crore.

Balance Sheet Highlights

The company’s shareholders' funds improved to ₹1,269.92 crore as of March 31, 2026, from ₹838.73 crore a year earlier. This increase was primarily driven by a rise in share capital to ₹203.53 crore and reserves and surplus to ₹1,066.39 crore. Total assets stood at ₹1,457.84 crore, up from ₹1,113.64 crore in the previous year.

Fund Utilization and Audit

Sheel Biotech raised ₹34.02 crore through an Initial Public Offer (IPO) during the year ended March 31, 2026. Of the funds raised, ₹31.28 crore was applied for the purposes stated in the prospectus, while a balance of ₹2.74 crore remained unutilized as of the balance sheet date. The statutory auditor, S S Mangla & Co LLP, issued an unqualified opinion on the financial statements, confirming that they give a true and fair view of the company's state of affairs.

The auditor reported that the company has not incurred cash losses in the financial year or the immediately preceding financial year. Additionally, the company has adequate internal financial controls over financial reporting, which were operating effectively as of March 31, 2026.

Sheel Biotech Limited has formally executed a Memorandum of Understanding (MoU) with the Indian Council of Agricultural Research – Central Institute for Subtropical Horticulture (ICAR-CISH), Lucknow. The agreement falls under the “Fruit Horizon” program and was officially delivered on May 20, 2026, completing the procedural formalities that followed the initial signing on May 7, 2026.

The signing ceremony was attended by key dignitaries, including the Union Minister for Agriculture & Farmers’ Welfare and Rural Development, Shri Shivraj Singh Chouhan. State Ministers for agriculture and horticulture, along with senior officials from ICAR and the Director of CISH, Lucknow, were also present. Dr. Anju Bajpai, Principal Scientist & Head of the Division of Crop Improvement & Biotechnology, presented the MoU regarding technology commercialization.

Strategic Implications

This partnership is anticipated to enhance Sheel Biotech 's strategic positioning in the sector of fruit innovation. The collaboration focuses on technology commercialization, which is expected to contribute significantly to the company's long-term growth trajectory.

Key Details of the Agreement

The company has submitted the necessary intimation to the National Stock Exchange of India Limited pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.